Technology
Health
Biotechnology
CASI Pharmaceuticals
$3.309876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
$0.00 (0.00%) Today
Why Robinhood?
You can buy or sell CASI and other stocks, options, ETFs, and crypto commission-free!
About
CASI Pharmaceuticals, Inc. Common Stock, also called CASI Pharmaceuticals, is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market. Read More The firm develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. The drugs are Captisol-Enabled, ZEVALIN and MARQIBO. The company was founded in 1991 and is headquartered in Rockville, MD.
Employees
51
Headquarters
Rockville, Maryland
Founded
1991
Market Cap
308.22M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
502.27K
High Today
$3.32
Low Today
$3.23
Open Price
$3.32
Volume
28.47K
52 Week High
$8.89
52 Week Low
$2.73
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Cancer Prevention
Medical
Pharmaceutical
News
MarketBeatMar 10
Stock Price, News, & Analysis for CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer. The company's late-stage clinical drug candidates, including EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoieti...
Yahoo FinanceFeb 20
Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett — Future Expectations, Projections Moving into 2019
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Pure Storage, Inc. (PSTG), Flowers Foods, Inc. (FLO), Cognex Corporation (CGNX), CASI Pharmaceuticals, Inc. (CASI), Ellie Mae, Inc. (ELLI), and Douglas Emmett, Inc. (DEI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research....
Price Paid on Robinhood
27% Lower
Right Now
52 Week Low
$2.73
Average Price Paid
$4.49
52 Week High
$8.89
Earnings
-$0.10
-$0.07
-$0.03
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
Available Mar 29, Pre-Market